{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-020362","form_type":"8-K","ticker":"OGEN","cik":"0001174940","company_name":"ORAGENICS INC","filed_at":"2024-05-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.539732+00:00","generated_at":"2026-06-01T14:34:00.599575+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Oragenics to host Neurotrauma Medicine webinar; will present ONP-002 mTBI update","bullets":["Webinar scheduled for May 20, 2024, at 12:00 PM ET.","Lead drug candidate ONP-002, a neurosteroid for mild TBI, to be discussed.","Company to review preclinical/Phase I data and provide details on upcoming Phase II trial in acute/emergency settings.","No financial results or regulatory milestones announced."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-020362","json":"https://secwatch.observer/filing/0001493152-24-020362.json","markdown":"https://secwatch.observer/filing/0001493152-24-020362.md","text":"https://secwatch.observer/filing/0001493152-24-020362.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1174940/000149315224020362/0001493152-24-020362-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1174940/000149315224020362/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T14:34:00.599575+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}